Related references
Note: Only part of the references are listed.Awakening the guardian of genome: reactivation of mutant p53
Akshay Binayke et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2019)
Small Molecules Targeting Mutant P53: A Promising Approach for Cancer Treatment
Elizabeth A. Lopes et al.
CURRENT MEDICINAL CHEMISTRY (2019)
Restoration of conformation of mutant p53
J. A. Green et al.
ANNALS OF ONCOLOGY (2018)
Monoclonal Antibodies against Specific p53 Hotspot Mutants as Potential Tools for Precision Medicine
Le-Ann Hwang et al.
CELL REPORTS (2018)
When the guardian sleeps: Reactivation of the p53 pathway in cancer
Olaf Merkel et al.
MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH (2017)
Putting p53 in Context
Edward R. Kastenhuber et al.
CELL (2017)
Novel Methods to Generate Active Ingredients-Enriched Ashwagandha Leaves and Extracts
Sunil C. Kaul et al.
PLOS ONE (2016)
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Patricia A. J. Muller et al.
CANCER CELL (2014)
Critical role for p53-serine 15 phosphorylation in stimulating transactivation at p53-responsive promoters
Jayne Loughery et al.
NUCLEIC ACIDS RESEARCH (2014)
Unravelling mechanisms of p53-mediated tumour suppression
Kathryn T. Bieging et al.
NATURE REVIEWS CANCER (2014)
Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments
G. Madhavi Sastry et al.
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN (2013)
Small molecule induced reactivation of mutant p53 in cancer cells
Xiangrui Liu et al.
NUCLEIC ACIDS RESEARCH (2013)
Effect of Y220C Mutation on p53 and Its Rescue Mechanism: A Computer Chemistry Approach
Shah Md Abdur Rauf et al.
PROTEIN JOURNAL (2013)
Ashwagandha Derived Withanone Targets TPX2-Aurora A Complex: Computational and Experimental Evidence to its Anticancer Activity
Abhinav Grover et al.
PLOS ONE (2012)
Mortalin-p53 interaction in cancer cells is stress dependent and constitutes a selective target for cancer therapy
W-J Lu et al.
CELL DEATH AND DIFFERENTIATION (2011)
Induction of mutant p53-dependent apoptosis in human hepatocellular carcinoma by targeting stress protein mortalin
Wen-Jing Lu et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
SCH529074, a Small Molecule Activator of Mutant p53, Which Binds p53 DNA Binding Domain (DBD), Restores Growth-suppressive Function to Mutant p53 and Interrupts HDM2-mediated Ubiquitination of Wild Type p53
Mark Demma et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Selective Killing of Cancer Cells by Ashwagandha Leaf Extract and Its Component Withanone Involves ROS Signaling
Nashi Widodo et al.
PLOS ONE (2010)
TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use
Magali Olivier et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2010)
Selective killing of cancer cells by leaf extract of Ashwagandha: Components, activity and pathway analyses
Nashi Widodo et al.
CANCER LETTERS (2008)
Transcriptional control of human p53-regulated genes
Todd Riley et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2008)
Targeted rescue of a destabilized mutant of p53 by an in silico screened drug
Frank M. Boeckler et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Structure-function-rescue: the diverse nature of common p53 cancer mutants
A. C. Joerger et al.
ONCOGENE (2007)
Selective killing of cancer cells by leaf extract of ashwagandha: Identification of a tumor-inhibitory factor and the first molecular insights to its effect
Nashi Widodo et al.
CLINICAL CANCER RESEARCH (2007)
A standardized root extract of Withania somnifera and its major constituent withanolide-A elicit humoral and cell-mediated immune responses by up regulation of Th1-dominant polarization in BALB/c mice
Fayaz Malik et al.
LIFE SCIENCES (2007)
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Wen Xue et al.
NATURE (2007)
Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints
Jirina Bartkova et al.
NATURE (2006)
Structural basis for understanding oncogenic p53 mutations and designing rescue drugs
Andreas C. Joerger et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Destabilizing missense mutations in the tumour suppressor protein p53 enhance its ubiquitination in vitro and in vivo
Harumi Shimizu et al.
BIOCHEMICAL JOURNAL (2006)
Mortalin-based cytoplasmic sequestration of p53 in a nonmammalian cancer model
C Walker et al.
AMERICAN JOURNAL OF PATHOLOGY (2006)
Bcl-2 but not clusterin/apolipoprotein J protected human diploid fibroblasts and immortalized keratinocytes from ceramide-induced apoptosis: Role of p53 in the ceramide response
E Kolettas et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2006)
The Amber biomolecular simulation programs
DA Case et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2005)
How many mutant p53 molecules are needed to inactivate a tetramer?
WM Chan et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Development and testing of a general amber force field
JM Wang et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2004)
Post-translational modification of p53 in tumorigenesis
AM Bode et al.
NATURE REVIEWS CANCER (2004)
Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation
CL Brooks et al.
CURRENT OPINION IN CELL BIOLOGY (2003)
The p53 stabilizing compound CP-31398 induces apoptosis by activating the intrinsic bax/mitochondrial/caspase-9 pathway
Y Luu et al.
EXPERIMENTAL CELL RESEARCH (2002)
Hsp70 family member, mot-2/mthsp70/GRP75, binds to the cytoplasmic sequestration domain of the p53 protein
R Wadhwa et al.
EXPERIMENTAL CELL RESEARCH (2002)
A peptide that binds and stabilizes p53 core domain:: Chaperone strategy for rescue of oncogenic mutants
A Friedler et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
VJN Bykov et al.
NATURE MEDICINE (2002)
An N-terminal region of mot-2 binds to p53 in vitro
SC Kaul et al.
NEOPLASIA (2001)
Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy
AN Bullock et al.
ONCOGENE (2000)
Share Paper
